Top Markets
#1 Islamic Coin Islamic Coin +151.55%
#2 Black Phoenix Black Phoenix +25.61%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.62%
#4 Fake World Assets Fake World Assets +16.15%
#5 Akedo Akedo +12.71%
#6 OpenEden OpenEden +12.39%
#7 clBTC clBTC +11.98%
#8 Palladium Network Palladium Network +11.96%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.81%
#10 Pons Pons +11.07%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFI
Rangering i aksjer #40134
Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge,... Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
Aksjekurs
$0.0039
Sist synkronisert: 2023-10-27
Markedsverdi
$235.97K
Endring (1 dag)
-13.33%
Endring (1 år)
0.00%
Land
US
Handel Infinity Pharmaceuticals, Inc. (INFI)

Kategori

Healthcare
P/E-forhold for Infinity Pharmaceuticals, Inc. (INFI)
P/E-forhold per 2026 TTM: 0
Ifølge Infinity Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Infinity Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.